AZN
ASTRAZENECA PLC
- PER (TTM)
- 27.54
- PER (Forward)
- 30.97
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 5.98
- 시가총액
- 283.47B
- 배당수익률
- 173.00%
- 베타
- 0.22
- 1개월 수익률
- -10.80%
- 3개월 수익률
- -4.29%
- 6개월 수익률
- 13.84%
- 1년 수익률
- 32.75%
- 2년 수익률
- -
- 5일 평균거래량
- 2048700
- 60일 평균거래량
- 2012403
- 1년 평균거래량
- 2511046
- 5d/60d 거래량 비율
- 1.02×
- 60d/1y 거래량 비율
- 0.80×
- 변동성(60일, 연환산)
- 21.67%
- BB 스퀴즈 스코어
- 1.48
- SMA50 비율
- 0.94
- SMA200 비율
- 1.03
- RSI (14)
- 37
- 20일 수렴도
- 0.04
- 52주 최고
- 208.62
- 52주 최저
- 130.19
- 고점 대비
- -12.35%
- 저점 대비
- 40.45%
펀더멘털 갱신: 2026-05-10T07:51:02+00:00 · 시세 갱신: 2026-05-10T06:10:31+00:00
회사 정보
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.